Allan Gibofsky, MD, JD, MACR, FACP, FCLM; Bruce E. Sands, MD, MS
This activity is jointly provided by Global Education Group and Integritas Communications.
Supported by an educational grant from Gilead Sciences, Inc.
With increasing evidence showing that the Janus kinase (JAK) inhibition can be used as a target for certain immune-mediated diseases, this activity reviews the benefits and safety concerns gastroenterologists and rheumatologists need to consider.
This activity has been designed to meet the educational needs of gastroenterologists and rheumatologists who care for patients with inflammatory bowel disease or rheumatoid arthritis.
After completing this activity, the participant should be better able to:
- Describe the roles of various JAK-STAT signal transduction pathways in immune dysregulation and chronic inflammatory processes
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine and Public Health
Weill Department of Medicine
Healthcare Policy and Research
Weill Medical College of Cornell University
Adjunct Professor of Law
Fordham University School of Law
Hospital for Special Surgery & New York-Presbyterian Hospital
New York, New York
Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Allan Gibofsky, MD, JD, MACR, FACP, FCLM: Consultant/Advisor: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Iroko Pharmaceuticals, LLC; Pfizer Inc. Speakers Bureau: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Novartis Pharmaceuticals Corporation; Pfizer Inc. Stocks: AbbVie Inc.; Bristol-Myers Squibb Company; Pfizer Inc.
Bruce E. Sands, MD, MS: Consultant/Advisor: AbbVie Inc.; Allergan; Arena Pharmaceuticals; Boehringer-Ingelheim; Eli Lilly and Company; Ferring Pharmaceuticals; Gilead Sciences, Inc.; Janssen; Otsuka Pharmaceutical; Pfizer, Inc.; R&D Systems; Synergy Pharmaceuticals; Takeda Pharmaceutical Company; Theravance Biopharma; TiGenix Grant/Research Support (paid to institution): Celgene Honoraria: Takeda Pharmaceutical Company
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose
Julia Muino: Nothing to disclose
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 0.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.25
credit type CME/CE
Think You Know JAK?